大摩:中生製藥(1177.HK)第三季收入符預期 經常性盈利略遜
摩根士丹利發表報告指,中生製藥(01177.HK)第三季收入按年增長13%,符合該行預期,但由於税務開支增加及少數股東權益較高,季度經常性盈利按年升17%,則略遜預期。該行維持對集團的“增持”評級及目標價12.5港元。
大摩表示,根據中生製藥管理層稱,集團有三種藥品或會於國家醫保藥品目錄的談判清單上,若獲納入醫保目錄,每種藥品每年可產生超過10億元人民幣的銷售額,加上推出的新藥銷售,該行認為足以抵銷藥品Alprostadil(Kaishi)從醫保目錄中移除,及第二輪藥品集中採購帶來的負面影響,相信可支持集團盈利在明年及2021年有15%至20%的健康增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.